Amicus Therapeutics/$FOLD
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Amicus Therapeutics
Amicus Therapeutics Inc is a patient-dedicated biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare diseases. With extraordinary patient focus, the company is committed to advancing and expanding a pipeline of cutting-edge medicines for rare diseases. It has a portfolio of product opportunities, including oral precision medicine for people living with Fabry disease who have amenable genetic variants; a clinical-stage, treatment paradigm for Pompe disease, and a rare disease gene therapy portfolio. The company has one segment focused on the discovery, development, and commercialization of therapies to treat a range of devastating rare and orphan diseases.
Ticker
$FOLD
Sector
Primary listing
Employees
499
Headquarters
Website
FOLD Metrics
BasicAdvanced
$2.7B
-
-$0.12
0.51
-
Price and volume
Market cap
$2.7B
Beta
0.51
52-week high
$11.63
52-week low
$5.51
Average daily volume
5.5M
Financial strength
Current ratio
3.209
Quick ratio
2.009
Long term debt to equity
212.774
Total debt to equity
216.988
Interest coverage (TTM)
0.53%
Profitability
EBITDA (TTM)
32.949
Gross margin (TTM)
90.37%
Net profit margin (TTM)
-6.67%
Operating margin (TTM)
4.39%
Effective tax rate (TTM)
-69.26%
Revenue per employee (TTM)
$1,140,000
Management effectiveness
Return on assets (TTM)
2.00%
Return on equity (TTM)
-22.62%
Valuation
Price to revenue (TTM)
4.656
Price to book
13.07
Price to tangible book (TTM)
-294.71
Price to free cash flow (TTM)
-54.362
Free cash flow yield (TTM)
-1.84%
Free cash flow per share (TTM)
-0.159
Growth
Revenue change (TTM)
25.35%
Earnings per share change (TTM)
-68.74%
3-year revenue growth (CAGR)
21.16%
10-year revenue growth (CAGR)
113.30%
3-year earnings per share growth (CAGR)
-49.98%
10-year earnings per share growth (CAGR)
-18.76%
What the Analysts think about FOLD
Analyst ratings (Buy, Hold, Sell) for Amicus Therapeutics stock.
Bulls say / Bears say
Total net product revenues for Q2 2025 were $154.7 million, up 18% at constant exchange rates, marking the 17th consecutive quarter of double-digit CER growth (GlobeNewswire).
Pombiliti + Opfolda net product sales jumped 63% year-over-year to $25.8 million, supported by strong demand and launches in five new countries (GlobeNewswire).
The pivotal Phase 3 study for DMX-200 in focal segmental glomerulosclerosis is expected to finish enrollment by year-end, expanding Amicus’s rare disease pipeline and diversifying future revenue streams (GlobeNewswire).
GAAP operating expenses rose 48% to $148.9 million, while non-GAAP operating expenses increased 56% to $127.8 million, reflecting increased cash burn from higher R&D and licensing costs (GlobeNewswire).
The company posted a GAAP net loss of $24.4 million in Q2 2025, wider than the $15.7 million loss a year earlier, highlighting persistent unprofitability (GlobeNewswire).
Pombiliti + Opfolda full-year 2025 revenue guidance was revised downward to 50–65% CER growth from the previous 65–85%, citing delayed patient starts in new markets and higher-than-expected U.K. VPAG rebates, pointing to execution risks (GlobeNewswire).
Data summarised monthly by Lightyear AI. Last updated on 29 Sept 2025.
FOLD Financial Performance
Revenues and expenses
FOLD Earnings Performance
Company profitability
FOLD News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Amicus Therapeutics stock?
Amicus Therapeutics (FOLD) has a market cap of $2.7B as of October 26, 2025.
What is the P/E ratio for Amicus Therapeutics stock?
The price to earnings (P/E) ratio for Amicus Therapeutics (FOLD) stock is 0 as of October 26, 2025.
Does Amicus Therapeutics stock pay dividends?
No, Amicus Therapeutics (FOLD) stock does not pay dividends to its shareholders as of October 26, 2025.
When is the next Amicus Therapeutics dividend payment date?
Amicus Therapeutics (FOLD) stock does not pay dividends to its shareholders.
What is the beta indicator for Amicus Therapeutics?
Amicus Therapeutics (FOLD) has a beta rating of 0.51. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.